Clinical trialNCT06450041RecruitingPhase 2Interventional

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

SponsorNew Approaches to Neuroblastoma Therapy ConsortiumEnrollment62Neuroblastoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Keri Streby, MD
Nationwide Children's Hospital
Study Chair
clinicaltrials.gov ↗
Mark Ranalli, MD
Nationwide Children's Hospital
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Los Angeles
Los Angeles, California, United States
Recruiting
Ucsf Benioff Children'S Hospital
San Francisco, California, United States
Recruiting
Children'S Hospital Colorado
Aurora, Colorado, United States
Recruiting
Comer Children'S Hospital, University of Chicago
Chicago, Illinois, United States
Not, yet, recruiting
Boston Children'S Hospital, Dana-Farber Cancer Institute.
Boston, Massachusetts, United States
Not, yet, recruiting
C.S Mott Children'S Hospital
Ann Arbor, Michigan, United States
Not, yet, recruiting
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Not, yet, recruiting
Nationwide Children'S Hospital
Columbus, Ohio, United States
Recruiting
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Recruiting
St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
Recruiting
University of Texas Southwestern
Dallas, Texas, United States
Recruiting
Cook Children'S Medical Center
Fort Worth, Texas, United States
Recruiting
Seattle Children'S Hospital
Seattle, Washington, United States
Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

DinutuximabGM-CSFIrinotecan →Temozolomide →Universal Donor TGFβi NK Cells

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Dec 2024
Primary completion: 31 Dec 2028
Completion: 31 Dec 2038
Last update posted: 20 Jul 2026
Registered enrollment: 62
Registry id: NCT06450041

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.